BPH / Enlarged Prostate Clinical Trials

Cross-section illustration of a normal prostate and open urethra — Normal Prostate Gland

Cross-section illustration of stage 1 benign prostatic hyperplasia — Stage 1 BPH

Cross-section illustration of stage 2 benign prostatic hyperplasia — Stage 2 BPH

Cross-section illustration of stage 3 benign prostatic hyperplasia — Stage 3 BPH

Walnuts on a green background illustrating prostate size comparison

A Randomized, International Study to Assess the Safety of iTind Compared to UroLift (MT-08)

Minimally invasive procedures such as UroLift and iTind can relieve lower urinary tract symptoms (LUTS) caused by benign prostatic enlargement. This study compares the safety of iTind with UroLift in patients for whom treatment is appropriate.

General Requirements

Diagnosis of lower urinary tract symptoms presumed to be secondary to benign prostatic enlargement causing bladder outlet obstruction for which treatment is recommended
Males 50 years of age or older
Screening PSA < 4 ng/mL
Prostate volume up to 75 cc documented by TRUS or MRI

NCT04757116

Diagram of the TULSA-PRO procedure showing ultrasound applicator and thermal ablation of the prostate

Customized TULSA-PRO Ablation Registry

Data from patients who have undergone or are undergoing transurethral ultrasound ablation (TULSA) as part of clinical care are entered into this registry to evaluate long-term safety, effectiveness, and quality of life.

General Requirements

Male
>18 years old
Candidate for TULSA-PRO treatment
Willing and able to sign the Informed Consent Form

NCT05001477